10-Q: Savara Reports Q3 Losses, Secures Funding, Resubmits BLA

Savara Inc. reported increased net losses for Q3 and the nine months ended September 30, 2025, while securing significant post-period funding and planning to resubmit its MOLBREEVI BLA in December 2025 following an FDA Refusal to File.

Summary

• Net loss for the three months ended September 30, 2025, increased to $29.6 million from $24.2 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $86.6 million from $66.8 million in the prior year period.
• Accumulated deficit reached approximately $575.9 million as of September 30, 2025.
• Research and development expenses increased by 1.4% to $20.6 million for Q3 2025 and by 10.5% to $60.5 million for the nine months ended September 30, 2025, primarily due to manufacturing, regulatory affairs, and quality assurance activities.
• General and administrative expenses significantly increased by 60.1% to $9.6 million for Q3 2025 and by 71.8% to $29.5 million for the nine months ended September 30, 2025, driven by personnel additions and commercial activities.
• Cash and cash equivalents were $16.3 million and short-term investments were $108.1 million as of September 30, 2025.
• Subsequent to the reporting period, on October 31, 2025, Savara completed a public offering raising approximately $140.0 million in net proceeds.
• On October 29, 2025, Savara entered into a Royalty Purchase and Sale Agreement for $75.0 million, contingent upon FDA approval of MOLBREEVI by March 31, 2027.
• The FDA issued a Refusal to File (RTF) letter for the MOLBREEVI Biologics License Application (BLA) in May 2025, but the company plans to resubmit in December 2025 and request Priority Review.
• MOLBREEVI holds Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations.

Sentiment

Score: 4

Explanation: While the company secured significant post-period funding, the increased net losses, higher operating expenses, and the FDA's Refusal to File for its sole product candidate, MOLBREEVI, indicate significant operational and regulatory challenges. The ongoing litigation and potential impacts of the government shutdown add further uncertainty.

Positives

• Secured significant post-period funding of approximately $140.0 million from a public offering and a potential $75.0 million from a royalty agreement, substantially improving liquidity.
• MOLBREEVI has received multiple favorable regulatory designations, including FDA Fast Track, Breakthrough Therapy, and Orphan Drug, as well as EMA Orphan Drug and UK MHRA Innovation Passport and Promising Innovative Medicine designations.
• The FDA's Refusal to File for MOLBREEVI was not due to safety concerns and did not request additional efficacy studies, suggesting a path forward for resubmission.
• Current cash and short-term investments, combined with recent capital raises, are sufficient to fund operations for at least the next twelve months.

Negatives

• Net loss increased to $29.6 million for Q3 2025 and $86.6 million for the nine months ended September 30, 2025, compared to prior year periods.
• Accumulated deficit grew to $575.9 million as of September 30, 2025, reflecting continued operating losses since inception.
• Operating expenses, particularly General and Administrative, increased significantly, indicating higher cash burn.
• The FDA issued a Refusal to File (RTF) letter for the MOLBREEVI BLA in May 2025, delaying the regulatory approval process.
• A stockholder filed a putative securities class action lawsuit on September 8, 2025, alleging violations related to public statements about MOLBREEVI BLA filings.

Risks

• Uncertainty regarding FDA or foreign regulatory approval for MOLBREEVI, which could be denied or delayed, materially impacting business.
• Need for additional capital to fund future operating expenses, clinical development, and commercialization activities, with no assurance of availability on favorable terms.
• Exposure to securities-related class action and derivative lawsuits, which are costly to defend, divert management resources, and have an uncertain outcome.
• Potential adverse impact from the U.S. federal government shutdown on FDA operations, which could delay the acceptance or review of the MOLBREEVI BLA resubmission.
• Risks inherent in life science companies, including successful discovery and development of drug candidates, competition, protection of proprietary technology, and market acceptance.
• Obligations under the Hercules Loan Agreement include covenants related to maintaining unrestricted cash and achieving revenue milestones, with potential for acceleration of repayment upon default.
• Reliance on third-party manufacturers (FujiFilm, GEMA, PARI) and contract research organizations (Parexel) for development and manufacturing, subject to contractual terms and potential supply issues.

Future Outlook

The company plans to resubmit its Biologics License Application (BLA) for MOLBREEVI in December 2025 and request Priority Review, following the FDA's Refusal to File in May 2025. It expects to incur significant additional expenses and continue operating losses for several years as it advances MOLBREEVI through clinical development, seeks regulatory approval, and invests in commercialization infrastructure and supply for potential launch in the United States and European Union. Future funding requirements will depend on clinical development pace and results, and the company may need to raise additional capital beyond its current resources.

Management Comments

• We are currently focused on the development of MOLBREEVI for the treatment of autoimmune PAP and believe such activities will result in the continued incurrence of significant research and development, regulatory and other expenses related to this program.
• Our cash and cash equivalents and short-term investments are sufficient to fund our operations for at least the next twelve months subsequent to the issuance date of these condensed consolidated financial statements.
• We intend to cover our future operating expenses through cash and cash equivalents on hand, short-term investments, and through a combination of equity offerings, debt financings, government or other third-party funding, and other collaborations and strategic alliances with partner companies.
• We intend to vigorously defend against such allegations in the securities class action lawsuit.

Industry Context

Savara Inc. operates in the highly specialized and capital-intensive biopharmaceutical industry, focusing on rare respiratory diseases. The development of novel therapies like MOLBREEVI for autoimmune PAP is characterized by lengthy and costly clinical trials, stringent regulatory hurdles, and a high risk of failure. The company's reliance on outsourcing manufacturing and clinical operations is a common strategy for clinical-stage biotechs to manage overhead. The FDA's Refusal to File highlights the significant regulatory challenges, even for drugs with Breakthrough Therapy designation, underscoring the inherent risks in bringing new treatments to market. The recent capital raises are critical in an industry where sustained funding is essential to navigate development and commercialization pathways.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global industry benchmarks.

Corporate Governance

Legal Proceedings

• On September 8, 2025, a stockholder filed putative securities class action claims against the company and certain executive officers in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges violations of the Securities Exchange Act of 1934 and Rule 10b-5 related to public statements about MOLBREEVI regulatory and BLA filings, seeking unspecified damages, costs, and attorneys' fees. The company intends to vigorously defend against these allegations.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity offerings, but also benefit from improved liquidity and the potential for significant returns if MOLBREEVI achieves regulatory approval and commercial success. The ongoing litigation introduces uncertainty and potential costs.
• Employees are impacted by the company's continued focus on MOLBREEVI development and potential commercialization, with stock-based compensation plans in place to incentivize performance. Increased G&A expenses reflect strategic personnel additions.
• Future customers (patients with autoimmune PAP) stand to benefit from a new treatment option if MOLBREEVI successfully gains regulatory approval and is commercialized.
• Creditors, such as Hercules Capital and RTW Investments, have their returns tied to the company's ability to achieve regulatory milestones and generate product revenue, as per the terms of the loan and royalty agreements.
• Suppliers and contract organizations (e.g., FujiFilm, GEMA, PARI, Parexel) continue to be engaged for manufacturing and clinical trial services, indicating ongoing operational activity and commitment to MOLBREEVI's development.

Next Steps

• Resubmit the MOLBREEVI BLA to the FDA in December 2025 and request Priority Review.
• Continue funding clinical development and pursuing regulatory approval for MOLBREEVI.
• Invest in commercialization infrastructure and supply chain for MOLBREEVI.
• Prepare for commercial launch activities in the United States and European Union.
• Defend against the putative securities class action claims filed on September 8, 2025.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial position, results of operations, and cash flows.

Key Dates

Recommendation

The company faces significant headwinds, including increased losses, an FDA Refusal to File, and ongoing litigation. However, the recent substantial capital raise of $140 million and the $75 million royalty agreement (contingent on FDA approval) provide a crucial liquidity runway. MOLBREEVI's Breakthrough Therapy and Orphan Drug designations still offer a path to market, and the planned BLA resubmission with Priority Review is a key near-term catalyst. Given the high-risk, high-reward nature of clinical-stage biopharma, and the recent funding mitigating immediate liquidity concerns, a 'Hold' recommendation is appropriate for investors awaiting the outcome of the BLA resubmission and further clarity on commercialization.

Keywords

Savara Inc., SVRA, biopharmaceutical, rare respiratory diseases, MOLBREEVI, autoimmune PAP, FDA, BLA, clinical trial, Phase 3, financial results, Q3 2025, capital raise, stock offering, royalty agreement, litigation, Refusal to File